AstraZeneca Pharmaceuticals, LP v. Lopez
| ASTRAZENECA PHARMACEUTICALS, LP |
| ANNE E. LOPEZ, in her official capacity as the Attorney General of the State of Hawaii |
| UNITED STATES OF AMERICA, PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA, AMERICAN HOSPITAL ASSOCIATION, 340B HEALTH, HEALTHCARE ASSOCIATION OF HAWAII and AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS |
| 26-1172 |
| February 27, 2026 |
| U.S. Court of Appeals, Ninth Circuit |
| Constitutionality of State Statutes |
Docket Report
RSS Track this Docket
This docket was last retrieved on August 20, 2026. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 43 RESPONSE to notice of case being considered for oral argument filed by Allon Kedem. [Entered: 08/20/2026 11:51 AM] |
| Filing 42 NOTICE: This case is being considered for an upcoming oral argument calendar in Honolulu. Please review the Honolulu sitting dates for December 2026 and the subsequent sitting month in that location at #https://www.ca9.uscourts.gov/cases/calendar. Absent an irreconcilable conflict, the court expects you to appear and argue your case during one of these two months. If you have an irreconcilable conflict on any of the dates, please consult with opposing counsel to propose an alternate date and/or location and file Form 32 (#https://cdn.ca9.uscourts.gov/datastore/uploads/forms/form32.pdf) within 3 business days of this notice using the ACMS filing type Response to Case Being Considered for Oral Argument. Please follow the form's instructions (#https://cdn.ca9.uscourts.gov/datastore/uploads/forms/form32instructions.pdf) carefully. If the parties wish to discuss settlement before an argument date is set, they should jointly request referral to the mediation unit by filing a motion within 3 business days of this notice, using the filing type: Motion to Refer to Mediation. You will receive notice that your case has been assigned to a calendar approximately 10 weeks before the scheduled oral argument date. [26-1172] [Entered: 08/17/2026 10:42 AM] |
| Filing 41 RESPONSE to Citation of Supplemental Authorities (28j Letter) (DE 40) filed by Appellant AstraZeneca Pharmaceuticals, LP. [Entered: 07/16/2026 01:59 PM] |
| Filing 40 CITATION of Supplemental Authorities (28j Letter) filed by Appellee Anne E. Lopez. [Entered: 07/10/2026 03:04 PM] |
| Filing 39 CITATION of Supplemental Authorities (28j Letter) filed by Appellee Anne E. Lopez. [Entered: 06/05/2026 02:48 PM] |
| Filing 38 CLERK ACTION: Redacted Reply Brief submitted at DE 36 by Appellant AstraZeneca Pharmaceuticals, LP is filed. No paper copies are required. [Entered: 05/28/2026 10:41 AM] |
| Filing 37 CLERK ACTION: Redacted Opening Brief submitted at DE 35 by Appellant AstraZeneca Pharmaceuticals, LP is filed. No paper copies are required. [Entered: 05/28/2026 10:41 AM] |
| Filing 36 REPLY BRIEF submitted for filing by Appellant AstraZeneca Pharmaceuticals, LP. [Entered: 05/27/2026 10:08 AM] |
| Filing 35 OPENING BRIEF submitted for filing by Appellant AstraZeneca Pharmaceuticals, LP. [Entered: 05/27/2026 10:05 AM] |
| Filing 34 CLERK ACTION: Reply Brief submitted at DE 30 by Appellant AstraZeneca Pharmaceuticals, LP is filed UNDER SEAL. No paper copies are required. [Entered: 05/26/2026 11:17 AM] |
| Filing 33 CLERK ACTION: Answering Brief and Excerpts of Record submitted at DE 21, DE 22 by Appellee Anne E. Lopez are filed. No paper copies are required. [Entered: 05/26/2026 11:16 AM] |
| Filing 32 CLERK ACTION: Opening Brief and Excerpts of Record submitted at DE 12, DE 13, DE 14 by Appellant AstraZeneca Pharmaceuticals, LP are filed (Opening Brief and Volume 3 UNDER SEAL). No paper copies are required. [Entered: 05/26/2026 11:15 AM] |
Filing 31
ORDER FILED. Lisa B. Fitzgerald, Appellate Commissioner. The unopposed motions (Docket Entry Nos. 11, 29) to file under seal the unredacted opening and reply briefs and Volume 3 of the excerpts of record are granted. The clerk will file publicly the motions to seal (Docket Entry Nos. 11.1, 29.1), Volumes 1 through 2 of the excerpts of record (Docket Entry No. 12), the answering brief (Docket Entry No. 21), and the supplemental excerpts of record (Docket Entry No. 22). The clerk will maintain the unredacted opening and reply briefs, and Volume 3 of the excerpts of record under seal at Docket Entry Nos. 13, 14, and 30. Within 21 days of this order, appellant must submit for public filing redacted versions of the opening and reply briefs that track the proposed redactions highlighted in Docket Entry Nos. 11.2 and 29.2. The page numbering and citations in the public briefs must remain the same as in the sealed briefs. [Entered: 05/26/2026 07:39 AM]
|
| Filing 30 REPLY BRIEF UNDER SEAL submitted for filing by Appellant AstraZeneca Pharmaceuticals, LP. (Court entered filing of sealed brief submitted at DE 29) [Entered: 05/15/2026 05:14 PM] |
| Filing 29 MOTION to File Document Under Seal and Sealed Document Submitted for Filing filed by Appellant AstraZeneca Pharmaceuticals, LP.--[COURT UPDATE: UNSEALED 29.1 per DE 31] [Entered: 05/15/2026 03:49 PM] [Edited: 05/26/2026 07:41 AM] |
| Filing 28 NOTICE OF APPEARANCE by William B. Schultz for Amicus Curiae - Pending 340B Health, Amicus Curiae - Pending American Hospital Association, Amicus Curiae - Pending American Society of Health-System Pharmacists, Amicus Curiae - Pending Healthcare Association of Hawaii. [Entered: 05/05/2026 07:05 AM] |
| Filing 27 ADDED Amici Curiae - Pending American Hospital Association, 340B Health, Healthcare Association of Hawaii, and American Society of Health-System Pharmacists, with counsel William B. Schultz. [Entered: 05/04/2026 11:38 AM] |
| Filing 26 DEFECTIVE --- AMICUS BRIEF and MOTION for leave to file amicus brief filed by American Society of Health-System Pharmacists.--[Duplicate entry, correct entry is DE 23] [Entered: 05/01/2026 11:27 AM] [Edited: 05/04/2026 11:40 AM] |
| Filing 25 DEFECTIVE --- AMICUS BRIEF and MOTION for leave to file amicus brief filed by Healthcare Association of Hawaii.--[Duplicate entry, correct entry is DE 23] [Entered: 05/01/2026 11:25 AM] [Edited: 05/04/2026 11:40 AM] |
| Filing 24 DEFECTIVE --- AMICUS BRIEF and MOTION for leave to file amicus brief filed by 340B Health.--[Duplicate entry, correct entry is DE 23] [Entered: 05/01/2026 11:22 AM] [Edited: 05/04/2026 11:40 AM] |
| Filing 23 AMICUS BRIEF and MOTION for leave to file amicus brief filed by American Hospital Association, 340B Health, Healthcare Association of Hawaii, and American Society of Health-System Pharmacists.--[COURT UPDATE: Updated docket text to reflect all amici] [Entered: 05/01/2026 11:20 AM] [Edited: 05/04/2026 11:39 AM] |
| Filing 22 EXCERPTS OF RECORD submitted for filing by Appellee Anne E. Lopez. [Entered: 04/24/2026 06:54 PM] |
| Filing 21 ANSWERING BRIEF submitted for filing by Appellee Anne E. Lopez. [Entered: 04/24/2026 06:52 PM] |
| Filing 20 CLERK ACTION: Amicus Brief submitted at DE 16 by Pharmaceutical Research and Manufacturers of America is filed. No paper copies are required. [Entered: 04/06/2026 10:04 AM] |
| Filing 19 ADDED Amicus Curiae Pharmaceutical Research and Manufacturers of America, Counsel for Amicus Curiae Erin E. Murphy, Counsel for Amicus Curiae Matthew Rowen, Counsel for Amicus Curiae Philip Hammersley [Entered: 04/06/2026 09:47 AM] |
| Filing 18 CLERK ACTION: Amicus Brief submitted at DE 15 by United States of America is filed. No paper copies are required. [Entered: 04/06/2026 09:11 AM] |
| Filing 17 ADDED Amicus Curiae United States of America, Counsel for Amicus Curiae Maxwell A. Baldi [Entered: 04/03/2026 05:01 PM] |
| Filing 16 AMICUS BRIEF by government or with consent submitted for filing by Pharmaceutical Research and Manufacturers of America. [Entered: 04/03/2026 11:41 AM] |
| Filing 15 AMICUS BRIEF by government or with consent submitted for filing by United States of America. [Entered: 04/03/2026 08:23 AM] |
| Filing 14 EXCERPTS OF RECORD Vol 3 UNDER SEAL submitted for filing by Appellant AstraZeneca Pharmaceuticals, LP. (Court entered filing of sealed vol submitted at DE 11) [Entered: 03/30/2026 02:16 PM] |
| Filing 13 OPENING BRIEF UNDER SEAL submitted for filing by Appellant AstraZeneca Pharmaceuticals, LP. (Court entered filing of sealed brief submitted at DE 11) [Entered: 03/30/2026 01:56 PM] |
| Filing 12 EXCERPTS OF RECORD submitted for filing by Appellant AstraZeneca Pharmaceuticals, LP.--[COURT UPDATE: Corrected PDF of vol 2 attached as of 3/30/2026, REPLACING original attachment] [Entered: 03/27/2026 02:36 PM] [Edited: 03/30/2026 01:54 PM] |
| Filing 11 MOTION to File Document Under Seal and Sealed Document Submitted for Filing filed by Appellant AstraZeneca Pharmaceuticals, LP.--[COURT UPDATE: Corrected PDF files of motion and brief attached as of 3/30/2026, REPLACING original attachments] [Entered: 03/27/2026 02:34 PM] [Edited: 03/30/2026 01:53 PM] |
| Filing 10 ADDED Counsel for Appellee Thomas J. Hughes, Counsel for Appellee Kalikoonalani Diara Fernandes [Entered: 03/18/2026 09:12 AM] |
| Filing 9 NOTICE OF APPEARANCE by Kalikoonalani Diara Fernandes for Appellee Anne E. Lopez. [Entered: 03/17/2026 07:17 PM] |
| Filing 8 NOTICE OF APPEARANCE by Thomas J. Hughes for Appellee Anne E. Lopez. [Entered: 03/17/2026 07:16 PM] |
| Filing 7 RELEASED FROM MEDIATION (text only). This case is released from the Mediation Program. [Entered: 03/16/2026 10:12 AM] |
| Filing 6 MEDIATION CONFERENCE SCHEDULED - DIAL-IN Assessment Conference, 3/19/2026, 11:00 a.m. PACIFIC Time. See order for instructions and details. [Entered: 03/10/2026 04:20 PM] |
| Filing 5 DISCLOSURE STATEMENT pursuant to FRAP 26.1 and CR 26.1-1 filed by Appellee Anne E. Lopez. [Entered: 03/05/2026 12:35 PM] |
| Filing 4 MEDIATION QUESTIONNAIRE filed by Appellant AstraZeneca Pharmaceuticals, LP. To submit pertinent confidential information directly to the Circuit Mediators, please email #[email protected] and include the case name and number in the subject line. Confidential submissions may include any information relevant to mediation of the case and settlement potential, including, but not limited to, settlement history, ongoing or potential settlement discussions, non-litigated party related issues, other pending actions, and timing considerations that may impact mediation efforts. [Entered: 03/02/2026 12:12 PM] |
| Filing 3 DISCLOSURE STATEMENT pursuant to FRAP 26.1 and CR 26.1-1 filed by Appellant AstraZeneca Pharmaceuticals, LP. [Entered: 03/02/2026 12:08 PM] |
| Filing 2 PRELIMINARY INJUNCTION SCHEDULE NOTICE. Preliminary Injunction Opening Brief Due (Appellant) 3/27/2026, Preliminary Injunction Answering Brief Due (Appellee) 4/24/2026, Mediation Questionnaire due (Appellant) 3/4/2026. For appeal no. 26-1172, 1:25-cv-00369-MWJS-WRP.All briefs shall be served and filed pursuant to FRAP 31 and 9th Cir. R. 31-2.1. Failure of the petitioner(s)/appellant(s) to comply with this briefing schedule will result in automatic dismissal of the appeal. See 9th Cir. R. 42-1. [Entered: 02/27/2026 04:26 PM] |
| Filing 1 CASE OPENED. A copy of your notice of appeal / petition filed in 1:25-cv-00369-MWJS-WRP has been received in the Clerk's office of the United States Court of Appeals for the Ninth Circuit. The U.S. Court of Appeals docket number 26-1172 has been assigned to this case. All communications with the court must indicate this Court of Appeals docket number. Please carefully review the docket to ensure the name(s) and contact information are correct. It is your responsibility to alert the court if your contact information changes. Resources Available For more information about case processing and to assist you in preparing your brief, please review the Case Opening Information (for #attorneys and #pro se litigants) and review the #Appellate Practice Guide. Attorneys should consider contacting the court's #Appellate Mentoring Program for help with the brief and argument. [Entered: 02/27/2026 04:23 PM] |
Access additional case information on PACER
Access the Case Summary and Docket Report to access additional information about this case on the U.S. Court's PACER system. A subscription to PACER is required.
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
